Search clinical trials for: VX-509 matching placebo

Total 1905 results

Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Germany, Australia, France, Italy, Czechia, Austria, Greece, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Cystic Fibrosis | Advanced Lung Disease

United States
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States
Syneos Health
Shanghai Novamab Biopharmaceuticals Co. Ltd.

Terminated

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Asthma

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Vaxon Biotech

Completed

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Non-small Cell Lung Cancer Metastatic

Germany, Greece, Spain, Romania, France, Italy, Czechia, Poland
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Drugs for Neglected Diseases
Bayer

Active, not recruiting

Emodepside Phase II Trial for Treatment of Onchocerciasis

Onchocerciasis

Ghana, Congo, The Democratic Republic of the
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
EIP Pharma Inc
National Institute on Aging (NIA); Worldwide Clinical Trials; CervoMed, Inc

Recruiting

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, United Kingdom, Netherlands
Hannover Medical School
Heidelberg University; University of Giessen

Completed

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor (OrkambiFacts)

Cystic Fibrosis

Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United Kingdom
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
Laboratoires Pronutri
Clin-Experts; Plateforme Cocolab

Completed

Effects of Dietary Supplements Based on Trace Elements on Voice Parameters and Some Psychological and Physiological Parameters Related to Stress - Single-center, Comparative, Cross-over, Randomized, Double-blind Study Versus Placebo, in Healthy Subjects

Stress

France
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Microneurography (MNG) Study of VX-150 in Healthy Participants

Pain

United Kingdom
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
New Beta Innovation Limited

Terminated

YQ23 Study in Patients With Critical Limb Ischaemia (YAN)

Critical Limb Ischemia

Hong Kong
SIMR (Australia) Biotech Pty Ltd.

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

Healthy Volunteers

Australia
Bayer

Completed

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

Japan
Bayer

Completed

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Cough

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Schizophrenia

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Spain, Germany, Italy, Austria, Belgium, Denmark
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Celldex Therapeutics

Recruiting

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Prurigo Nodularis

United States
Merit E. Cudkowicz, MD
Ra Pharmaceuticals

Completed

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Biohaven Pharmaceuticals, Inc.

Completed

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Amyotrophic Lateral Sclerosis

United States
New Beta Innovation Limited

Completed

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Terminated

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, United Kingdom, United States
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.

Completed

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Urinary Incontinence

United States
Icahn School of Medicine at Mount Sinai
Sanofi; Regeneron Pharmaceuticals; Rockefeller University

Completed

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Alopecia Areata

United States
Sangamo Therapeutics

Completed

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Polyneuropathy

United States, Mexico

3

Subscribe